SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1694>>Full article from Medscape on the cost effectiveness of the three glycopIcebrg-7/2/2003
1693<i> "costs" or do you also mean "prices"? </i> HSpekulatius-7/2/2003
1692Full article from Medscape on the cost effectiveness of the three glycoprotein Ituck-7/2/2003
1691<i>There are huge opportunities to reduce costs in developing countries anjayhawk969-7/2/2003
1690Pharma cost in the US are: 30% Sales and Marketing 30% Profit (pretax) 15% ProduSpekulatius-7/1/2003
1689<<For a non-US deal this is about as best as could be expected.>> TMiljenko Zuanic-7/1/2003
16889:31AM MLNM upfront payment misleading -- Ryan Beck 13.83 -1.90: Ryan Beck beliSemiBull-7/1/2003
1687If all goes okay, MLNM should get get about $400-500 MM and if this drug goes grRobohogs-7/1/2003
1686Millennium Pharmaceuticals Inc. (MLNM) ----------------------------------------smh-7/1/2003
1685I wonder how many shares abt sold today-maybe thats why the stock price is decliMadharry-7/1/2003
1684I agree. This guy drives me nuts. Everytime I read his MLNM / ABT opinions, I JFitnich-7/1/2003
1683Peter and Quid, Thanks for the clarification re analog. OT to Peter: WSJ has Ian@SI-7/1/2003
1682Robert V. Green, Briefing.com I wonder what deal this guy is looking at. MilleIcebrg-7/1/2003
1681Would agree with Peter's edit on a non-technical interpretation of the termsquidditch-7/1/2003
1680Ian, I'd guess that by "analogues" they mean tweaked versions of Biomaven-7/1/2003
1679Peter During MLNM's conference call, one of the Q dealt with just what JNJ Ian@SI-7/1/2003
1678Another take on the deal: 10:51 ET Millennium Pharmaceuticals (MLNM): $13.79 -1Czechsinthemail-7/1/2003
1677<i> J&J oncology expertise</i> Well they do have some oncology Biomaven-7/1/2003
1676You're talking about reality. I'm hoping that all those that wish to Ian@SI-7/1/2003
1675Oh Ian, quit your kidding. You know that you would have to wait for Velcade to Bill Hermesmann-7/1/2003
1674J&J deal Having slept on the matter the deal still looks fairly good to me Icebrg-7/1/2003
1673I am talking about drug future value, as market potential and drug economic (proMiljenko Zuanic-7/1/2003
1672<< Today US economic is ~40-50% of worldwide >> % of the world ecDavid Howe-7/1/2003
1671<< MLNM retained all commercial rights for Velcade in the US (which represMiljenko Zuanic-7/1/2003
1670Thanks PCSS. But Sales and Ice beat GS to deadline, and with more detail. :-keokalani'nui-7/1/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News